Author: Nagai, Kazumasa; Kitamura, Katsuya; Hirai, Yuji; Nutahara, Daisuke; Nakamura, Hironori; Taira, Junichi; Matsue, Yubu; Abe, Masakazu; Kikuchi, Miho; Itoi, Takao
Title: Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19 Cord-id: nawf61jh Document date: 2020_11_23
ID: nawf61jh
Snippet: Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV
Document: Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.
Search related documents:
Co phrase search for related documents- active treatment and locally advanced: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date